Chronic Refractory Cough
Chronic Refractory Cough Market

Chronic Refractory Cough is defined as a cough lasting quite 8 weeks that persists despite guidelines-based treatment which can be treated by different medical specialties: Pulmonology, Allergy, and Immunology, Digestive Health, and Otorhinolaryngology. Patients with chronic cough experience impaired quality of life and interruption of activities of daily living. 

 

Chronic Refractory Cough Epidemiological Segmentation

The Epidemiological Segmentation of Chronic Refractory Cough in 7MM from 2018 to 2030 is segmented as:-

  • Prevalent Population of Chronic Refractory Cough
  • Gender-specific Prevalent Population of Chronic Refractory Cough 
  • Prevalent Population of Chronic Refractory Cough
  • Diagnosed Prevalent Population of Chronic Refractory Cough
  • Diagnosed Prevalent Population of Chronic Refractory Cough in Idiopathic Pulmonary Fibrosis (IPF) patients 

 

Chronic Refractory Cough Epidemiology (2020)

  • The total incident population of Chronic Refractory Cough in 7MM was 84,854,266.
  • Gender-specific Chronic Refractory Cough Cases were observed in the United States:-
  • Males- 10,805,114 cases
  • Females- 29,213,828 - cases
  • The prevalent population of Chronic Refractory Cough in 7MM was 17,600,264.
  • The total number of Chronic Refractory Cough prevalent cases in the United States was found to be 2,700,052.
  • The total Chronic Refractory Cough prevalent cases in France were 8,799,771.
  • In the United Kingdom, the total number of Chronic Refractory Cough prevalent cases was observed to be 8,682,007.
  • The total number of Chronic Refractory Cough cases in Spain was estimated to be 5,708,813.


Chronic Refractory Cough Market

The therapeutic market of Chronic Refractory Cough in the seven major markets is expected to increase during the study period (2018–2030) with a CAGR of 6.57%

 

Chronic Refractory Cough Market Drivers

  • Pipeline activity
  • Efficient management guidelines

 

Chronic Refractory Cough Market Barriers

  • Poor pathophysiology
  • Psychological obstacles
  • Adverse events of current therapies
  • Patient and health care system burden
  • High rate of clinical trial failure

 

Chronic Refractory Cough Emerging Drugs

The emerging drugs of the Chronic Refractory Cough market are:

  • Gefapixant
  • Orvepitant Maleate
  • Blu-5937
  • S-600918
  • Bay1817080 (Eliapixant)

And several others.

 

Chronic Refractory Cough Key Players

The key players in the chronic refractory cough market are:

  • Merck
  • Nerre Therapeutics
  • Bellus Health
  • Shionogi
  • Bayer 

And several others.